Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker8note that this conference is being recorded. I will now turn the conference over to Morgan Morse, Investor Relations. Thank you, Morgan. You may begin.Speaker7Thank you, Daryl. Good morning and good afternoon. Thank you for joining us on our Q4 and full year 2025 earnings call. During today's call, we will make some forward-looking statements which are qualified by our safe harbor provision under the Private Securities Li ...

4Q & FY 2025 Financial Results & Business Update To add/change the picture: Transformative immunomodulating medicines for patients • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSP ...

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report finan ...

Core Insights - Immunocore Holdings plc announces the departure of Dr. David Berman, Executive Vice President of Research and Development, effective February 27, 2026, as he takes a new role at another biotech company [1] - The company will not seek a direct replacement for Dr. Berman but will streamline its R&D structure, promoting Dr. Mohammed Dar and Mark Moyer to Executive Vice President roles [2] Leadership Changes - Dr. Mohammed Dar, previously Chief Medical Officer, has extensive experience in leading clinical development and will now oversee expanded clinical development and regulatory strategies [4] - Mark Moyer, who has been with Immunocore since 2018, will become EVP, Chief Regulatory and Quality Officer, having led the regulatory strategy for KIMMTRAK, which is now approved in 39 countries [5] Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, particularly its lead product KIMMTRAK, which treats HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [6]

Core Insights - Immunocore is a commercial stage biotechnology company focused on developing transformative medicines, particularly through its innovative soluble TCR receptor bispecific platform, which has been validated both clinically and commercially [2][3] Company Strategy - The company aims to grow its product KIMMTRAK and prepare for potential new indications in melanoma, while also expanding its focus beyond melanoma into other tumor types [4] - Immunocore plans to unlock opportunities beyond oncology, indicating a broader strategic vision for its product applications [4] Future Outlook - The years 2026 to 2028 are identified as critical for the company, with several data catalysts expected to emerge during this period [3]

Transformative immunomodulating medicines for patients January 2026 To add/change the picture: • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSPACE or DELETE on the keyboard > Clic ...

Core Viewpoint - TCE's efficacy and commercialization capabilities in hematological malignancies have been fully validated, but several challenges remain for its widespread application in solid tumors [1] Group 1: Current Status of TCE - A total of 12 TCE therapies have been approved globally, with 10 in the US and 6 in China; 9 are for hematological malignancies and only 3 for solid tumors [1] - The application of TCE in solid tumors faces challenges such as targeting tumor-associated antigens (TAA) without harming healthy tissues, enhancing T cell infiltration in the tumor microenvironment, and overcoming immunosuppressive cells and cytokines that lead to T cell exhaustion [1] Group 2: Design Innovations Enhancing TCE Applicability - Non-full-length bispecific antibodies and 2+1 format designs have shown promise; Amgen's DLL3/CD3 bispecific antibody has been approved for SCLC, and MSD's Gocatamig has demonstrated high tumor response rates in later-line SCLC patients [2] - The "2+1" format design allows for precise control of CD3 affinity, with Xencor's XmAb platform advancing its pipeline to Phase III clinical trials [2] - TCR therapy, exemplified by Immunocore's KIMMTRAK, targets intracellular protein antigens and has received FDA approval for uveal melanoma, with potential for expansion into other indications [2] Group 3: Strategies to Mitigate Toxicity and Enhance Efficacy - Prodrug designs are being explored to reduce off-target toxicity; Janux has validated its TCE in clinical settings, and Vir's VIR-5818 shows promising initial data in HER2-positive breast cancer [3] - Co-stimulatory signals from CD28, 4-1BB, and CD2 are expected to enhance TCE responses; Regeneron's CD28 bispecific antibody strategy has shown effectiveness but raised safety concerns [3] - Selective T cell activation targets are being developed to avoid broad T cell activation risks; AstraZeneca and LavaTherapeutics are working on TCEs that selectively target CD8+ T cells and Vγ9Vδ2 T cells [4] Group 4: Domestic Companies and Pipeline Development - Domestic companies are advancing TCE research with diverse technical paths, including CD28 co-stimulatory bispecific antibodies and TCR therapies, forming a robust pipeline [5] - Companies to watch include Zai Lab, Wuxi Biologics, Heng Rui Medicine, Bai Li Tianheng, and others, indicating a rich landscape for TCE development in solid tumors [5]

Summary of Immunocore Holdings Conference Call Company Overview - **Company**: Immunocore Holdings (NasdaqGS:IMCR) - **Focus**: A commercial stage biotech company specializing in T-cell engager platform for oncology and infectious diseases, as well as autoimmune conditions. [4][6] Key Products and Pipeline - **KIMMTRAK**: - Approved for uveal melanoma in 38 markets, launched in 28 markets. [4] - Achieved over $100 million in sales for the first time in the last quarter. [10] - Currently has a duration of therapy of about 14 months, exceeding clinical trial results. [11] - 68% penetration in the US market, with higher penetration in European markets (80-90%). [14][15] - Two ongoing Phase 3 trials for cutaneous melanoma and adjuvant settings. [5][16] - **PRAME**: - In Phase 3 for first-line cutaneous melanoma, showing promising monotherapy activity. [22] - Ongoing trials in ovarian and lung cancers, with data expected next year. [24] Commercial Performance - **KIMMTRAK Sales**: - Growth driven by both US and international markets, with significant contributions from recent launches in the UK, Netherlands, and Poland. [10] - Safety profile has contributed to increased duration of therapy and penetration in community settings. [11] Clinical Trials and Data - **Cutaneous Melanoma**: - Phase 3 trial shows a one-year overall survival (OS) rate of 75% compared to 55% for comparators. [16] - Enrollment expected to finish in the first half of 2026, with data anticipated in the second half of 2026. [16] - **Adjuvant Setting**: - Focus on preventing metastasis in high-risk patients post-surgery. [18] - **PRAME BiSpecific**: - Ongoing Phase 3 trial in combination with Nivolumab, with data expected around the end of 2027 or early 2028. [26] Infectious Disease and Autoimmune Programs - **Infectious Disease**: - Programs in HIV and HBV, with promising single ascending dose data for HBV showing surface antigen reduction. [30] - Aim for a functional cure in HIV by targeting viral reservoirs. [31] - **Autoimmune**: - Focus on tissue-specific down modulation, with a Type 1 diabetes program targeting T-cell activity in the pancreas. [34] - Plans to initiate clinical trials next year. [35] Financial Position - **Cash Position**: - As of Q3, Immunocore holds $892 million in cash, indicating a strong financial position to support ongoing operations and R&D. [40] Upcoming Milestones - Key milestones for 2026 include: - Completion of the cutaneous melanoma trial with KIMMTRAK. - Data releases for HIV, PRAME, ovarian, and lung cancer programs. [38] Conclusion - Immunocore is positioned for significant growth with a robust pipeline and strong commercial performance of KIMMTRAK, alongside promising developments in PRAME and infectious disease programs. The company maintains a solid financial foundation to support its strategic initiatives. [41]